YT-19/20

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameYT-19/20
Drug Alias NameDual Anti-CD19/Anti-CD20 CAR-T Cell Therapy (China Immunotech)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionB-lymphocyte antigen CD20 modulatorsB-lymphocyte antigen CD19 modulators
TargetsB-lymphocyte antigen CD19B-lymphocyte antigen CD20
Therapy Area/IndicationsLymphoma, Large B-Cell, DiffuseLymphoma, B-CellLymphoma, Non-Hodgkin +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesChina Immunotech Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesChina Immunotech Co Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, Large B-Cell, DiffuseLymphoma, B-CellLymphoma, Non-Hodgkin +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A